by Clinical Neuropsychologist | Friday, November 22, 2024 | Dementia
Abstract INTRODUCTION While the role of apolipoprotein E (APOE) ε4 in Alzheimer’s disease (AD) susceptibility has been studied extensively, much less is known about the differences in disease presentation in APOE ε4 carriers versus non-carriers. METHODS To help...
by Clinical Neuropsychologist | Thursday, November 21, 2024 | Dementia
Abstract BACKGROUND Peak-width of skeletonized mean diffusivity (PSMD), a neuroimaging marker of cerebral small vessel disease (SVD), has shown excellent instrumental properties. Here, we extend our work to perform a biological validation of PSMD. METHODS We included...
by Clinical Neuropsychologist | Wednesday, November 20, 2024 | Dementia
Abstract Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer’s disease (AD) patients. The AMYPAD consortium set out to integrate...
by Clinical Neuropsychologist | Tuesday, November 19, 2024 | Dementia
Abstract INTRODUCTION Patterns of signal from tau positron emission tomography (tau-PET) confined to the medial temporal lobe (MTL) or extended into the neocortex may be relevant for Alzheimer’s disease (AD) research if they are linked to differential biomarker...
by Clinical Neuropsychologist | Tuesday, November 19, 2024 | Dementia
Abstract INTRODUCTION Progression to Alzheimer’s disease (AD) dementia from normal cognition (NC) can follow different trajectories, with most progressing through a recognizable mild cognitive impairment stage (NC–MCI–AD), while some individuals transition...
